1. Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis
- Author
-
Neda Dadgar, Christopher Sherry, Jenna Zimmerman, Hyun Park, Catherine Lewis, Albert Donnenberg, Ali H. Zaidi, Yong Fan, Kunhong Xiao, David Bartlett, Vera Donnenberg, and Patrick L. Wagner
- Subjects
IL-6 ,Peritoneal carcinomatosis ,Targeted therapy ,Tumor immune microenvironment ,Medicine - Abstract
Abstract Peritoneal carcinomatosis (PC) is a complex manifestation of abdominal cancers, with a poor prognosis and limited treatment options. Recent work identifying high concentrations of the cytokine interleukin-6 (IL-6) and its soluble receptor (sIL-6-Rα) in the peritoneal cavity of patients with PC has highlighted this pathway as an emerging potential therapeutic target. This review article provides a comprehensive overview of the current understanding of the potential role of IL-6 in the development and progression of PC. We discuss mechansims by which the IL-6 pathway may contribute to peritoneal tumor dissemination, mesothelial adhesion and invasion, stromal invasion and proliferation, and immune response modulation. Finally, we review the prospects for targeting the IL-6 pathway in the treatment of PC, focusing on common sites of origin, including ovarian, gastric, pancreatic, colorectal and appendiceal cancer, and mesothelioma.
- Published
- 2024
- Full Text
- View/download PDF